Telomir Pharmaceuticals, Inc. 8-K

What Happened

• Telomir Pharmaceuticals (TELO) announced on May 20, 2026 (Form 8‑K Item 7.01) that a peer‑reviewed preclinical study titled “Intracellular copper redox modulation disrupts ROS–Ca²⁺ amplification in an ATP7B‑deficient zebrafish model of Wilson’s disease” was published in the journal Advances in Redox Research. The publication reports preclinical results for Telomir‑1 (Telomir‑Zn) in cellular systems and an ATP7B‑deficient zebrafish model.

Key Details

• Publication date / filing: Press release disclosed on May 20, 2026; Form 8‑K furnished under Item 7.01.
• Study model: Cellular systems and an ATP7B‑deficient zebrafish model of Wilson’s disease.
• Reported findings: reductions in oxidative stress signaling, correction of intracellular Ca²⁺ dysregulation, decreased hepatic copper accumulation, lower liver injury biomarkers and histopathological degeneration, and improved locomotor performance and survival in the zebrafish model.
• Administrative note: The information was furnished (Exhibit 99.1) and is not “filed” for purposes of Section 18 of the Exchange Act per General Instruction B.2.

Why It Matters

• For investors, this filing reports positive preclinical evidence for Telomir‑1 supporting its mechanism and potential in Wilson’s disease models, which may be relevant to the company’s preclinical/clinical development progress.
• It does not include human clinical data, financial results, or changes to guidance or management; the 8‑K is a disclosure of a published preclinical study rather than a regulatory filing for product approval.